Bristol-Myers Squibb Reports Results of Opdivo (nivolumab) in P-III CheckMate-459 Study as 1L Treatment for Patients with Unresectable Hepatocellular Carcinoma

 Bristol-Myers Squibb Reports Results of Opdivo (nivolumab) in P-III CheckMate-459 Study as 1L Treatment for Patients with Unresectable Hepatocellular Carcinoma

Bristol-Myers Squibb Reports Results of Opdivo (nivolumab) in P-III CheckMate-459 Study as 1L Treatment for Patients with Unresectable Hepatocellular Carcinoma

Shots:

  • The P-III CheckMate-459 study results involve assessing of Opdivo vs sorafenib as a 1L treatment in patients with unresectable hepatocellular carcinoma (HCC)
  • The P-III CheckMate-459 study results demonstrated that it did not meet its 1EPs of overall survival (OS) per the pre-specified analysis, no new safety signals were observed
  • Opdivo is PD-1 immune check inhibitor, harnessing the body’s own immune system to help restore anti-tumor immune response, being evaluated in multiple studies for HCC as monothx. or in combination with Yervoy (ipilimumab) for prior treated patients

Click here to read full press release/ article | Ref: BMS | Image: Record Journal

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post